Biotechnology Acquisitions in Arizona

Showing 4 transactions.

  • Buyer
    Ally Biotech
    Target
    Chill Pill (soft gel cap line)
    Seller
    Desert Medical Campus, Inc.
    Industry
    Biotechnology
    Location
    Arizona, United States
    Type
    Buyout

    Ally Biotech, a Payson, Arizona-based cannabinoid delivery company, acquired the Chill PillTM soft gel cap brand and related assets from Desert Medical Campus, Inc. in an all-cash transaction. The purchase adds a leading THC soft gel product line (distributed in ~40 Arizona dispensaries) to Ally Biotech’s Lipofusion delivery platform and supports planned product expansion and team integration in Payson, Arizona.

  • Buyer
    SCHOTT MINIFAB (SCHOTT)
    Target
    Applied Microarrays Inc.
    Industry
    Biotechnology
    Location
    Arizona, United States
    Type
    Buyout

    SCHOTT MINIFAB, a subsidiary of SCHOTT, has agreed to acquire Applied Microarrays Inc. (AMI), a Tempe, Arizona–based developer and manufacturer of DNA and protein microarrays and biosensors. The deal expands SCHOTT's bioscience and microarray printing capabilities and increases its manufacturing footprint in the United States to better support diagnostics and point-of-care customers.

  • Buyer
    IMV Technologies
    Target
    Genetirate
    Seller
    Genetirate, Hatch.Blue
    Industry
    Biotechnology
    Location
    Arizona, United States
    Type
    Buyout

    French animal-reproduction specialist IMV Technologies has acquired Genetirate, a U.S.-based aquaculture biotechnology startup founded at the University of Arizona. The deal brings Genetirate's metabolic-rate sorting technology into IMV's portfolio to accelerate sustainable aquaculture production, particularly for salmon and trout.

  • Buyer
    The Pritzker Organization, Pritzker Family Business Interests (advised by The Pritzker Organization)
    Target
    Systems Oncology, LLC
    Industry
    Biotechnology
    Location
    Arizona, United States
    Type
    Growth capital

    Pritzker Family Business Interests, advised by The Pritzker Organization, participated in the first closing of Systems Oncology's Series B financing. The growth capital will fund discovery research and pre-clinical development of Systems Oncology's AI-driven cancer therapeutics platform, and TPO will take a board seat.

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.